Efficacy and safety of Brentuximab Vedotin in advanced cutaneous T-Cell lymphomas patients

被引：1
|
作者：
Papadavid, E. [1 ]
Kapniari, E. [1 ]
Marinos, L. [2 ]
Nikolaou, V. [3 ]
Oikonomidi, A. [3 ]
Georgakopoulos, J. [4 ]
Stratigos, A. [3 ]
Kouloulias, V. [4 ]
Pappa, V. [5 ]
机构：
[1] Univ Athens, Dept Dermatol Venereol 2, Attikon Gen Univ Hosp, Athens, Greece
[2] Evaggelismos Gen Hosp, Hemato Pathol Dept, Athens, Greece
[3] Univ Athens, Syggros Hosp, Dept Dermatol Venereol 1, Athens, Greece
[4] Univ Athens, Attikon Gen Univ Hosp, Dept Radiol 2, Radiol Oncol, Athens, Greece
[5] Univ Athens, Attikon Gen Univ Hosp, Propedeut Dept 2, Hematol Unit, Athens, Greece
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2019年 / 33卷 / 05期
关键词：
MYCOSIS-FUNGOIDES;
D O I：
10.1111/jdv.15409
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E223 / E225
页数：4
相关论文
共 50 条
  • [1] Efficacy and safety of brentuximab vedotin plus bendamustine in advanced-stage primary cutaneous T-cell lymphomas
    Dumont, M.
    Ram-Wolff, C.
    Roelens, M.
    Brice, P.
    de Latour, R. Peffault
    Battistella, M.
    Madelaine, I.
    Delyon, J.
    Herms, F.
    Bouaziz, J. -D.
    Moins-Teisserenc, H.
    Lebbe, C.
    Bagot, M.
    de Masson, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (06) : 1315 - 1317
  • [2] Cutaneous T-Cell Lymphomas - under targeted Therapy with Brentuximab Vedotin and Mogamulizumab
    Bartels, P.
    Debus, D.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 51 - 51
  • [3] Intralesional brentuximab vedotin for the treatment of primary cutaneous T-cell lymphomas: a case series
    Arroyo-Andres, Jorge
    Agud-Dios, Manuel
    Rubio-Muniz, Carmen A.
    Postigo, Concepcion
    Cortijo-Cascajares, Susana
    Ortiz-Romero, Pablo L.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2024, 63 (02) : e57 - e59
  • [4] Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas
    Hasegawa, Gen
    Nakagawa, Noriharu
    Ueda, Yoshimichi
    Yamazaki, Masahide
    LEUKEMIA RESEARCH REPORTS, 2025, 23
  • [5] Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry
    Muniesa, Cristina
    Gallardo, Fernando
    Garcia-Doval, Ignacio
    Teresa Estrach, M.
    Combalia, Andrea
    Morillo-Andujar, Mercedes
    De la Cruz-Vicente, Fatima
    Machan, Salma
    Moya-Martinez, Cristina
    Rovira, Roger
    Sanchez-Gonzalez, Blanca
    Acebo, Elvira
    Amutio, Elena
    Penate, Yeray
    Del Carmen Losada-Castillo, Maria
    Pilar Garcia-Muret, M.
    Iznardo, Helena
    Roman-Curto, Concepcion
    Canueto, Javier
    Fernandez-de-Misa, Ricardo
    Florez, Angeles
    Maria Izu, Rosa
    Torres-Navarro, Ignacio
    Zayas, Ana
    Perez-Paredes, Gema
    Blanes, Mar
    Ignacio Yanguas, J.
    Perez-Ferriols, Amparo
    Callejas-Charavia, Marta
    Luis Ortiz-Romero, Pablo
    Perez-Gil, Amalia
    Prieto-Torres, Lucia
    Gonzalez-Barca, Eva
    Servitje, Octavio
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (01) : 57 - 64
  • [6] Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: data from the Spanish Primary Cutaneous Lymphoma Registry
    Muniesa, C.
    Gallardo, F.
    Garcia-Doval, I.
    Estrach, M. T.
    Combalia, A.
    Morillo-Andujar, M.
    De la Cruz Vicente, F.
    Machan, S.
    Moya-Martinez, C.
    Rovira, R.
    Sanchez-Gonzalez, B.
    Acebo, E.
    Amutio, E.
    Penate, Y.
    Losada-Castillo, M. C.
    Garcia-Muret, M. P.
    Iznardo, H.
    Roman-Curto, C.
    Canueto, J.
    Fernandez de Misa, R.
    Florez, A.
    Izu, R.
    Torres-Navarro, I.
    Zayas, A.
    Perez-Paredes, G.
    Blanes, M.
    Yanguas, J. I.
    Perez-Ferriols, A.
    Callejas-Charavia, M.
    Ortiz-Romero, Pl
    Perez-Gil, A.
    Prieto-Torres, L.
    Gonzalez-Barca, E.
    Servitje, O.
    EUROPEAN JOURNAL OF CANCER, 2022, 173 : S40 - S41
  • [7] Brentuximab vedotin — a new standard for cutaneous T-cell lymphoma
    David Killock
    Nature Reviews Clinical Oncology, 2017, 14 : 460 - 460
  • [8] Brentuximab vedotin - a Highly Potent Therapy for Cutaneous T-Cell-Lymphomas
    Pax, A.
    Stadler, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2014, 12 : 21 - 21
  • [9] Brentuximab vedotin - a highly potent Therapy for cutaneous T-Cell Lymphoma
    Pax, A. T.
    Stadler, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2014, 12 (12): : E6 - E6
  • [10] Phase II Trial Of Brentuximab Vedotin For CD30+Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders
    Duvic, Madeleine
    Tetzlaff, Michael
    Clos, Audra L.
    Gangar, Pamela
    Talpur, Rakhshandra
    BLOOD, 2013, 122 (21)
12345